Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The primary objective was to evaluate the long-term safety and tolerability of teriflunomide
when added to treatment with interferon-β [IFN-β] or glatiramer Acetate [GA] in patients with
multiple sclerosis [MS] with relapses.
Secondary objectives were to evaluate the long-term effect on relapse rate, disability
progression and Magnetic Resonance Imaging [MRI] parameters.
This study is the extension study of the PDY6045 (NCT00489489) and PDY6046 (NCT00475865)
studies. Participants who successfully completed the initial study were offered to continue
their treatment (same compound, same dose) for 24 additional weeks.